Skip to main content
. Author manuscript; available in PMC: 2012 Sep 15.
Published in final edited form as: Clin Cancer Res. 2011 Jul 26;17(18):6097–6105. doi: 10.1158/1078-0432.CCR-11-0930

Figure 4.

Figure 4

Changes in ceramide and S1P in patients with CR, PR or SD who have repeated measurements beyond cycle 3. The full spectrum of serum ceramide levels in patients with CR, PR and SD was measured at every 2 cycles of GEM/DOX treatment until the therapy was terminated using LC/MS/MS.